HOME >> BIOLOGY >> NEWS
Centocor & Schering-Plough next generation biologic promising in Phase 2 rheumatoid arthritis trial

SAN DIEGO, Calif., November 16, 2005 -- Results from a Phase 2 rheumatoid arthritis (RA) study assessing the safety and efficacy of golimumab (CNTO 148), a fully-human anti-TNF-alpha therapy, showed that it achieved the primary endpoint of the study. In this dose-ranging trial, more than 60 percent of patients with moderately to severely active RA treated with golimumab and methotrexate (MTX) experienced at least 20 percent improvement in arthritis symptoms at week 16. Additionally, one-quarter of patients receiving golimumab and MTX achieved remission as evaluated by Disease Activity Score 28 (DAS28). These findings will be presented this week at the American College of Rheumatology 2005 Annual Scientific Meeting.

"When treating a debilitating disease like RA, it is important to have several treatment options, and we are encouraged by the safety and efficacy data we have seen thus far for golimumab," said Jonathan Kay, MD, Director, Clinical Trials, Rheumatology Unit, Massachusetts General Hospital, Associate Clinical Professor of Medicine, Harvard University School of Medicine and lead study investigator.

Golimumab, developed by Centocor, Inc. and Schering-Plough, is a fully-human anti-TNF-alpha IgG1 monoclonal antibody that targets and neutralizes both the soluble and the membrane-bound form of TNF-alpha. Golimumab is currently being investigated for administration by either subcutaneous (SC) injection or intravenous (IV) infusion.

Data from the study showed that significantly more patients in all groups receiving SC injections of golimumab plus MTX achieved ACR 50 response (marked improvement in arthritis symptoms according to the American College of Rheumatology scoring criteria) versus patients receiving placebo plus MTX. Adults with active RA for at least three months' duration despite MTX therapy were randomized to one of five treatment groups: placebo every two weeks or golimumab 50 or 100 mg every two weeks or every four wee
'"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
16-Nov-2005


Page: 1 2 3 4

Related biology news :

1. ASBMB Schering-Plough Award lecture to focus on histone modifications in transcription
2. Cardiac patches stimulate regeneration, improve function after heart attack
3. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
4. Critical protein prevents DNA damage from persisting through generations
5. Early environmental exposure may accelerate age-related neurodegeneration
6. First demonstration of new hair follicle generation in an animal model
7. Enhanced environment restores memory in mice with neurodegeneration
8. Liver regeneration may be simpler than previously thought
9. Invasive grass may impede forest regeneration
10. Research project tackles regeneration gap
11. Whole body regeneration from a blood vessel

Post Your Comments:
(Date:6/25/2015)... 25, 2015  Imagine a tool specifically designed to ... happier life. That,s exactly what USANA,s True Health ... cutting-edge, portable health program provides a personalized approached to ... improve your lifestyle and nutrition. At ... Wednesday night, USANA,s THA was honored with the Industry ...
(Date:6/24/2015)... June 22, 2015 ... addition of the "Huawei Ascend Mate 7 ... to their offering. Huawei,s technological choice ... opposite direction than Apple,s and Samsung,s one. The ... developed by Fingerprint Cards, a main actor in ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, a ... authentication solutions, today announced enhanced functionality of its ... solution.  The enhancements build on the native ... DigitalPersona Altus platform and provide expanded mobile ... In today,s environment of increasing cyber-attacks ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
(Date:7/1/2015)... , July 1, 2015 InferMed ... technology will ... evidence-based clinical s olutions suite   ... and medical information products and services, announced today the acquisition ... decision support (CDS) technology company. InferMed,s Arezzo technology ...
(Date:6/30/2015)... July 1, 2015 R-Japan Co.,Ltd. obtained the license ... of Regenerative Medicine from the Ministry of Health, Labour and ... 2015. The fact that R- Japan ... the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on ... it to provide stem cell manufacturing service to medical institutions. ...
(Date:6/30/2015)... WASHINGTON , June 30, 2015  NASA astronaut ... launch next month on his first mission to the ... interviews from 8 to 9 a.m. EDT Tuesday, July 7. ... Center in Star City, Russia . The ... on NASA Television highlighting his mission training. To ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... does not sacrifice selectivity to achieve faster flow rates in comparison to nylon ... with significant open space to allow easy liquid flow while trapping particulates as ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
Cached News: